SOPHiA GENETICS (SOPH) Projected to Post Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH) is anticipated to post its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect SOPHiA GENETICS to post earnings of ($0.20) per share and revenue of $21.20 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:00 AM ET.

SOPHiA GENETICS Trading Down 3.2%

NASDAQ SOPH opened at $4.60 on Tuesday. The company has a 50 day moving average price of $4.94 and a 200 day moving average price of $4.38. The company has a quick ratio of 2.62, a current ratio of 2.80 and a debt-to-equity ratio of 0.78. SOPHiA GENETICS has a 52 week low of $2.58 and a 52 week high of $5.70. The firm has a market cap of $310.87 million, a PE ratio of -10.00 and a beta of 1.11.

Analyst Ratings Changes

A number of research firms have issued reports on SOPH. Guggenheim raised their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. BTIG Research lifted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Wall Street Zen upgraded shares of SOPHiA GENETICS to a “hold” rating in a research report on Saturday, November 1st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS during the third quarter worth $49,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS during the fourth quarter worth about $54,000. XTX Topco Ltd purchased a new stake in SOPHiA GENETICS during the 4th quarter valued at about $55,000. Susquehanna International Group LLP purchased a new stake in SOPHiA GENETICS during the 3rd quarter valued at about $88,000. Finally, Polen Capital Management LLC acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at about $102,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.